Intelligence · Patents
Patents expiring in 2045
Annual patent cliff calendar for 2045 — US pharmaceutical patents by expiration date.
- Patents
- 1,566
Quick answer
1,566 indexed pharmaceutical patents have expiration dates in 2045. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 12357590
Binge behavior regulators
granted -
US 12357615
Compositions for the treatment of brain tumors
granted -
US 12358979
Antibodies that bind interleukin 13 and methods of use
granted -
US 12357616
Methods of treating multiple sclerosis
granted -
US 12358863
Nitrogen-containing derivative of substituted phenol hydroxy acid ester, and preparation and use thereof
granted -
US 12357705
Negatively charged peg-lipid conjugates
granted -
US 12357687
Compositions and vaccines for treating and/or preventing viral infections, and methods of using the same
granted -
US 12358976
Methods for increasing serum concentration of phosphorous and/or 1,25-hydroxy vitamin d
granted -
US 12358988
Proteolytically cleavable chimeric polypeptides and methods of use thereof
granted -
US 12358931
3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor
granted -
US 12358879
Heterocyclic compound
granted -
US 12359223
Systems and methods for modulating chromosomal rearrangements
granted -
US 12359219
Transgene cassettes designed to express a human MECP2 gene
granted -
US 12357570
Chemoembolization agents
granted -
US 12357582
Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations
granted -
US 12357599
Prodrugs of treprostinil
granted -
US 12358921
Antiviral heterocyclic compounds
granted -
US 12358909
Capsazepine analogs for the treatment of cancer and other proliferative diseases
granted -
US 12358896
LRRK2 inhibitors and methods of making and using thereof
granted -
US 12358892
Metalloenzyme inhibitors for treating cancers, Alzheimer's disease, hemochromatosis, and other disorders
granted -
US 12358210
Resin composition for stereolithography
granted -
US 12357702
Peptidic diagnostic compositions
granted -
US 12357697
Pharmaceutical compositions comprising bupropion and cysteine
granted -
US 12357640
Pharmaceutical compositions comprising meloxicam
granted -
US 12357659
Production of megakaryocytes or platelets from monocytes
granted -
US 12357666
Traditional Chinese herbal plant composition for improving symptoms of liver cancer patients and compatibility method thereof
granted -
US 12357617
Discovery of novel anti-infectives for gram negative pathogens
granted -
US 12358952
Compositions and methods of synthesizing shape shifting cyclic peptides (Sscp) and their use in the identification of novel therapeutic compounds
granted -
US 12357703
Muscle-targeting complexes comprising an anti-transferin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping
granted -
US 12357682
DNA plasmid-launched live-attanuated vaccines for plus-sense singel stranded RNA
granted -
US 12357604
Topical formulations of cannabinoids and use thereof in the treatment of pain
granted -
US 12358885
Substituted n-propylamine fused heterocyclic mescaline derivatives
granted -
US 12357598
Treatment of neurodevelopmental disorders
granted -
US 12357650
Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorlylase inhibitors in combination with radiation
granted -
US 12357580
Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
granted -
US 12358968
Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer
granted -
US 12359178
Methods and compositions for treatment of hunter syndrome comprising iduronate-2-sulfatase
granted -
US 12357623
Method for treating a disease or condition using a pyrazole compound or formulation thereof
granted -
US 12359204
Soluble interleukin-7 receptor (SIL7R) modulating therapy to treat autoimmune diseases and cancer
granted -
US 12359220
Guided magnetic nanostructures for targeted and high-throughput intracellular delivery
granted -
US 12358971
Arena virus monoclonal antibodies and uses
granted -
US 12358928
Compounds, compositions and methods
granted -
AR 132581
COMPOSICIÓN INMUNÓGENA ÚTIL PARA LA AUTOADMINISTRACIÓN POR CERDOS
granted -
US 12365728
DLL3 single domain antibodies and therapeutic compositions thereof
granted -
US 12365930
Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
granted -
US 12365875
Methods for generating skeletal muscle progenitor cells
granted -
US 12365897
RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use
granted -
US 12365889
Tunable nanoscale cages from self-assembling DNA and protein building blocks
granted
Frequently asked questions
How many pharma patents expire in 2045?
1,566 published patents in our USPTO index have expiration dates falling in calendar year 2045.